DUBLIN, July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately 2.7billionoutstandingbalanceofitsU.S.dollartermloansunderitscreditfacility.TheapplicablemarginaboveTermSOFRwillbereducedby75basispoints(from300basispointsto225basispoints)andthecreditspreadadjustmentwillberemoved,resultinginanticipatedinterestsavingsofapproximately23 million on an annu ...